ASX Company Announcements

The edited text of our announcements are sourced from the Australian Stock Exchange and are delayed by at least 20 minutes. Retrieving the edited text of a company announcement indicates your acceptance of the Conditions.

Cellmid does not take any responsibility in respect of any of the edited text sourced from the Australian Stock Exchange


16 Oct 2017

 Cellmid Appoints Dr Martin Cross as Non-Executive Director  

 12 Oct 2017

 Date of Annual General Meeting

 03 Oct 2017

 Cellmid Receives $947K R&D Tax Credit

 03 Oct 2017

 Cellmid to Present at Proactive Investors Event

 27 Sep 2017

 2017 FY Results Investor Presentation

 25 Sep 2017

 Change of Share Registry Details

 30 Aug 2017

 Appendix 4E

 21 Aug 2017

 Cellmid Completes US Consumer Study

 03 Aug 2017

Cellmid Secures US Premium Retail for evolis

 01 Aug 2017

Cellmid Receives Chinese Import Permits

 28 Jul 2017

 Notes to Appendix 4C

 03 Jul 2017

 Nature Paper: MK in Melanoma

19 Apr 2017

 Notes to Appendix 4C

16 Mar 2017

 Change of Director's Interest Notice - Maria Halasz

02 Mar 2017

 Cellmids FGF5 Inhibitor Clinical Study Published

01 Mar 2017

 Cellmid to Refinance R&D Loan Facility

28 Feb 2017

 Appendix 4D and Half Year Accounts

07 Feb 2017 

 European Midkine Alopecia Patent Allowed

31 Jan 2017

 USA Midkine Alopecia Patent Allowed

24 Jan 2017

 Notes to Appendix 4C

18 Jan 2017

 Cellmid Receives Australian Government Grant For Midkine Programme

18 Jan 2017 

 Change of Director's Interest Notice - Maria Halasz